Tags

Type your tag names separated by a space and hit enter

A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Fertil Steril 2005; 83(2):321-30FS

Abstract

OBJECTIVE

To compare the effects of oral contraceptive (OC) pill pretreatment in recombinant FSH/GnRH-antagonist versus recombinant FSH/GnRH-agonist stimulation in in vitro fertilization (IVF) patients, and to evaluate optimization of retrieval day.

DESIGN

Prospective, randomized, multicenter study.

SETTING

Private practice and university centers.

PATIENT(S)

Eighty patients undergoing IVF who met the appropriate inclusion criteria.

INTERVENTION(S)

Four study centers recruited 80 patients. The OC regimen began on cycle days 2 to 4 and was discontinued on a Sunday after 14 to 28 days. The recombinant FSH regimen was begun on the following Friday. The GnRH-agonist group was treated with a long protocol; the GnRH-antagonist was initiated when the lead follicle reached 12 to 14 mm. When two follicles had reached 16 to 18 mm, hCG was administered.

MAIN OUTCOME MEASURE(S)

The primary outcome measures were the number of cumulus-oocyte complexes, day of the week for oocyte retrieval, and total dose and days of stimulation of recombinant FSH. Secondary efficacy variables included pregnancy and implantation rate; serum E(2) levels on stimulation day 1; serum E(2), P, and LH levels on the day of hCG administration; follicle size on day 6 and day of hCG administration; the total days of GnRH-analogue treatment; total days on OC; total days from end of OC to oocyte retrieval; and the cycle cancellation rate.

RESULT(S)

Patient outcomes were similar for the days of stimulation, total dose of gonadotropin used, two-pronuclei embryos, pregnancy (44.4% GnRH-antagonist vs. 45.0% GnRH-agonist, P=.86) and implantation rates (22.2% GnRH-antagonist vs. 26.4% GnRH-agonist, P=.71). Oral contraceptive cycle scheduling resulted in 78% and 90% of retrievals performed Monday through Friday for GnRH-antagonist and GnRH-agonist. A one day delay in OC discontinuation and recombinant FSH start would result in over 90% of oocyte retrievals occurring Monday through Friday in both groups.

CONCLUSION(S)

The OC pretreatment in recombinant FSH/GnRH-antagonist protocols provides a patient-friendly regimen and can be optimized for weekday retrievals. No difference was seen in number of 2PN embryos, cryopreserved embryos, embryos transferred, implantation and pregnancy rates between the two stimulation protocols.

Authors+Show Affiliations

Abington Reproductive Medicine, Abington, PA 19001, USA. lbarmat@abington-repromed.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15705369

Citation

Barmat, Larry I., et al. "A Randomized Prospective Trial Comparing Gonadotropin-releasing Hormone (GnRH) Antagonist/recombinant Follicle-stimulating Hormone (rFSH) Versus GnRH-agonist/rFSH in Women Pretreated With Oral Contraceptives Before in Vitro Fertilization." Fertility and Sterility, vol. 83, no. 2, 2005, pp. 321-30.
Barmat LI, Chantilis SJ, Hurst BS, et al. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril. 2005;83(2):321-30.
Barmat, L. I., Chantilis, S. J., Hurst, B. S., & Dickey, R. P. (2005). A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility, 83(2), pp. 321-30.
Barmat LI, et al. A Randomized Prospective Trial Comparing Gonadotropin-releasing Hormone (GnRH) Antagonist/recombinant Follicle-stimulating Hormone (rFSH) Versus GnRH-agonist/rFSH in Women Pretreated With Oral Contraceptives Before in Vitro Fertilization. Fertil Steril. 2005;83(2):321-30. PubMed PMID: 15705369.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. AU - Barmat,Larry I, AU - Chantilis,Samuel J, AU - Hurst,Bradley S, AU - Dickey,Richard P, PY - 2003/12/30/received PY - 2004/06/29/revised PY - 2004/06/29/accepted PY - 2005/2/12/pubmed PY - 2005/4/6/medline PY - 2005/2/12/entrez SP - 321 EP - 30 JF - Fertility and sterility JO - Fertil. Steril. VL - 83 IS - 2 N2 - OBJECTIVE: To compare the effects of oral contraceptive (OC) pill pretreatment in recombinant FSH/GnRH-antagonist versus recombinant FSH/GnRH-agonist stimulation in in vitro fertilization (IVF) patients, and to evaluate optimization of retrieval day. DESIGN: Prospective, randomized, multicenter study. SETTING: Private practice and university centers. PATIENT(S): Eighty patients undergoing IVF who met the appropriate inclusion criteria. INTERVENTION(S): Four study centers recruited 80 patients. The OC regimen began on cycle days 2 to 4 and was discontinued on a Sunday after 14 to 28 days. The recombinant FSH regimen was begun on the following Friday. The GnRH-agonist group was treated with a long protocol; the GnRH-antagonist was initiated when the lead follicle reached 12 to 14 mm. When two follicles had reached 16 to 18 mm, hCG was administered. MAIN OUTCOME MEASURE(S): The primary outcome measures were the number of cumulus-oocyte complexes, day of the week for oocyte retrieval, and total dose and days of stimulation of recombinant FSH. Secondary efficacy variables included pregnancy and implantation rate; serum E(2) levels on stimulation day 1; serum E(2), P, and LH levels on the day of hCG administration; follicle size on day 6 and day of hCG administration; the total days of GnRH-analogue treatment; total days on OC; total days from end of OC to oocyte retrieval; and the cycle cancellation rate. RESULT(S): Patient outcomes were similar for the days of stimulation, total dose of gonadotropin used, two-pronuclei embryos, pregnancy (44.4% GnRH-antagonist vs. 45.0% GnRH-agonist, P=.86) and implantation rates (22.2% GnRH-antagonist vs. 26.4% GnRH-agonist, P=.71). Oral contraceptive cycle scheduling resulted in 78% and 90% of retrievals performed Monday through Friday for GnRH-antagonist and GnRH-agonist. A one day delay in OC discontinuation and recombinant FSH start would result in over 90% of oocyte retrievals occurring Monday through Friday in both groups. CONCLUSION(S): The OC pretreatment in recombinant FSH/GnRH-antagonist protocols provides a patient-friendly regimen and can be optimized for weekday retrievals. No difference was seen in number of 2PN embryos, cryopreserved embryos, embryos transferred, implantation and pregnancy rates between the two stimulation protocols. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/15705369/A_randomized_prospective_trial_comparing_gonadotropin_releasing_hormone__GnRH__antagonist/recombinant_follicle_stimulating_hormone__rFSH__versus_GnRH_agonist/rFSH_in_women_pretreated_with_oral_contraceptives_before_in_vitro_fertilization_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(04)02875-4 DB - PRIME DP - Unbound Medicine ER -